ReviewCurrent oncology (Toronto, Ont.)2026
Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms.
Hikmat Abdel-Razeq et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.